Table 3.
HRs of Hepatocellular Carcinoma Development by HBV-Related Variables and Differently Adjusted Models
| Model | HBV DNA | HBeAg | ALT | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| All | |||||||||
| Unadjusted | 0.968 | 0.865–1.082 | 0.568 | 0.983 | 0.593–1.629 | 0.947 | 1.000 | 0.998–1.002 | 0.764 |
| Adjusted | |||||||||
| Model 1 | 1.030 | 0.920–1.153 | 0.609 | 1.381 | 0.824–2.313 | 0.221 | 1.001 | 0.999–1.003 | 0.368 |
| Model 2 | 1.031 | 0.920–1.154 | 0.712 | 1.379 | 0.823–2.311 | 0.222 | 1.001 | 0.999–1.003 | 0.364 |
| Model 3 | 1.092 | 0.975–1.223 | 0.129 | 1.369 | 0.820–2.285 | 0.229 | 1.001 | 0.999–1.003 | 0.244 |
| Model 4 | 1.097 | 0.947–1.271 | 0.217 | 1.201 | 0.693–2.084 | 0.514 | 1.000 | 0.994–1.006 | 0.800 |
| Model 5 | 1.057 | 0.911–1.226 | 0.464 | 1.032 | 0.599–1.779 | 0.909 | 1.001 | 0.994–1.007 | 0.876 |
| Model 6 | 1.059 | 0.913–1.227 | 0.451 | 1.046 | 0.606–1.803 | 0.873 | 1.000 | 0.993–1.007 | 0.734 |
| Without ongoing AVT at enrollment | |||||||||
| Unadjusted | 1.004 | 0.877–1.150 | 0.952 | 0.893 | 0.427–1.866 | 0.763 | 1.001 | 0.999–1.003 | 0.549 |
| Adjusted | |||||||||
| Model 1 | 1.079 | 0.941–1.238 | 0.275 | 1.223 | 0.579–2.581 | 0.598 | 1.001 | 0.999–1.003 | 0.306 |
| Model 2 | 1.080 | 0.941–1.238 | 0.274 | 1.222 | 0.579–2.581 | 0.598 | 1.001 | 0.999–1.003 | 0.305 |
| Model 3 | 1.116 | 0.967–1.288 | 0.134 | 1.090 | 0.515–2.306 | 0.821 | 1.001 | 0.999–1.003 | 0.240 |
| Model 4 | 1.120 | 0.942–1.332 | 0.199 | 0.914 | 0.399–2.095 | 0.831 | 1.002 | 0.994–1.009 | 0.674 |
| Model 5 | 1.057 | 0.889–1.257 | 0.531 | 0.681 | 0.303–1.527 | 0.351 | 1.003 | 0.995–1.011 | 0.425 |
| Model 6 | 1.059 | 0.891–1.260 | 0.514 | 0.702 | 0.313–1.573 | 0.390 | 1.002 | 0.994–1.010 | 0.617 |
| With Ongoing AVT at enrollment | |||||||||
| Unadjusted | 1.057 | 0.803–1.391 | 0.695 | 1.032 | 0.513–2.072 | 0.931 | 1.000 | 0.989–1.011 | 0.991 |
| Adjusted | |||||||||
| Model 1 | 1.128 | 0.850–1.498 | 0.404 | 1.529 | 0.742–3.151 | 0.250 | 1.003 | 0.992–1.013 | 0.648 |
| Model 2 | 1.126 | 0.847–1.496 | 0.415 | 1.522 | 0.738–3.139 | 0.255 | 1.002 | 0.992–1.013 | 0.664 |
| Model 3 | 1.182 | 0.909–1.536 | 0.212 | 1.721 | 0.846–3.501 | 0.134 | 1.000 | 0.987–1.014 | 0.961 |
| Model 4 | 1.030 | 0.722–1.468 | 0.871 | 1.523 | 0.712–3.260 | 0.278 | 0.994 | 0.974–1.014 | 0.556 |
| Model 5 | 1.030 | 0.722–1.468 | 0.871 | 1.523 | 0.712–3.260 | 0.278 | 0.994 | 0.974–1.014 | 0.556 |
| Model 6 | 1.029 | 0.721–1.470 | 0.874 | 1.517 | 0.708–3.250 | 0.283 | 0.994 | 0.974–1.014 | 0.567 |
HR, hazard ratio; HBV, hepatitis B virus; HBeAg, HBV e antigen; ALT, alanine aminotransferase; CI, confidence interval; AVT, antiviral therapy.
Model 1, age and gender; model 2, model 1 + diabetes mellitus; model 3, model 2 + cirrhosis; model 4, model 3 + α-fetoprotein, HBeAg positivity, HBV DNA, aspartate aminotransferase, alanine aminotransferase, serum albumin, total bilirubin, platelet count, and antiviral therapy AVT at enrollment; model 5, model 4 + AVT initiation after enrollment; model 6, model 5 + institution.